We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Observational Study of Kibow Biotics in Chronic Kidney Failure Patients on Dialysis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01450709
Recruitment Status : Completed
First Posted : October 12, 2011
Last Update Posted : August 20, 2019
State University of New York - Downstate Medical Center
Information provided by (Responsible Party):
Kibow Pharma

Brief Summary:
A specifically formulated probiotic product comprised of defined and tested microbial strains may afford renoprotection in what has been generally called "Enteric DialysisTM". However, it is also referred to as enteric toxin reduction technology. Our hypothesis is to assess the potential benefits in devising a bowel-based probiotic formulation (Kibow® Biotics/RenadylTM) as a dietary supplement product for patients undergoing dialysis along with standardized care of treatment.

Condition or disease Intervention/treatment
Chronic Kidney Disease Dietary Supplement: Kibow Biotics

Detailed Description:

Probiotics are increasingly utilized clinically. As their safety and health benefits are established, it is reasonable to anticipate that probiotic bacteria will be incorporated into a growing number of clinical regimens, as a dietary supplement.

Extensive in vitro R&D investigations in Kibow's laboratories

Bacterial strains studied were a mixture of patented and proprietary strains of Streptococcus thermophilus (KB27), Lactobacillus acidophilus (KB31) and Bifidobacterium longum (KB35).

Oral administration of these bacterial formulations, tested in the 5/6th nephrectomized rat model (at Thomas Jefferson University, Phila., PA) and minipig model (at Indiana University, Indianapolis, IN), decreased both blood urea nitrogen (BUN) and serum creatinine (Scr) levels.

Two independent veterinarians investigated the effect of Kibow Biotics® in cats and dogs (of both genders and varying body weights) with moderate to severe kidney failure. Based on positive results, this formulation, marketed and distributed as AzodylTM, is currently licensed for veterinary applications to Vetoquinol USA.

Pilot scale studies, double blind, placebo controlled, cross-over studies for six months conducted in 45 patients in USA, Canada, Argentina, and Nigeria demonstrates reduction of BUN (P>95%) and improved quality of life (P>95%). Decrease in creatinine and uric acid levels were also observed. However, these studies were based on correlating the age of geriatric cats and dogs with moderate to significant kidney failure to human geriatric conditions.

Layout table for study information
Study Type : Observational
Actual Enrollment : 30 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Observational Clinical Trials of Kibow Biotics® (a Patented and Proprietary Probiotic Formulation) in Dialysis Patients, in Conjunction With Standardized Care of Treatment
Actual Study Start Date : April 2011
Actual Primary Completion Date : September 2012
Actual Study Completion Date : October 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Dialysis

Group/Cohort Intervention/treatment
Dialysis patients Dietary Supplement: Kibow Biotics
6 month, double-blind, cross-over, wash-out, placebo controlled study in an outpatient setting. Each patient takes two capsules, three times a day (180 CFU/day).

Primary Outcome Measures :
  1. 15-20% Changes in BUN. [ Time Frame: 6 months ]
  2. 15-20% Changes in Creatinine [ Time Frame: 6 months ]
  3. 15-20% Changes in CRP [ Time Frame: 6 months ]
  4. 15-20% Changes in Uric Acid Levels [ Time Frame: 6 months ]

Secondary Outcome Measures :
  1. Quality of life outcome based on SF 36 questionnaire. [ Time Frame: 6 months ]
  2. To observe inflammatory and oxidative stress biomarkers. [ Time Frame: 6 months ]
    Observe inflammatory markers IL-1beta, NF-kappaB, Protein Bound Pentosidine, Beta2 Microglobulin, Indoxyl sulfate, Phenols, p-cresols, and guanadine metabolites from blood serum.

  3. Observation and analysis of patient fecal matter. [ Time Frame: 6 months ]
    Observation and analysis of patient fecal matter to determine bacterial flora levels that are present in the stool.

Biospecimen Retention:   Samples With DNA
Blood serum, plasma and lymphocytes.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Out patient hospital setting

Inclusion Criteria:

  • Currently on hemodialysis
  • 18 to 75 years of age
  • Willing to give informed consent
  • Baseline serum creatinine >2.5 mg/dL

Exclusion Criteria:

  • Pregnant or nursing women
  • Refusal to sign the informed consent form
  • Documented to have HIV/AIDS/Liver disease
  • Active dependency on drugs or alcohol
  • Currently on anticoagulant therapy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01450709

Layout table for location information
United States, New York
Parkside Dialysis Clinic at Downstate Medical Center
Brooklyn, New York, United States, 11226
Sponsors and Collaborators
Kibow Pharma
State University of New York - Downstate Medical Center
Layout table for investigator information
Principal Investigator: Subodh J Saggi, M.D., MPH Downstate Medical Center
Principal Investigator: Mary Mallapallil, M.D. Kings County Medical Center
Principal Investigator: Eli Friedman, M.D., MACP, FRCP Downstate Medical Center
Principal Investigator: Gary Briefel, M.D. Kings County Medical Center
Publications of Results:
Layout table for additonal information
Responsible Party: Kibow Pharma
ClinicalTrials.gov Identifier: NCT01450709    
Other Study ID Numbers: KIB004
First Posted: October 12, 2011    Key Record Dates
Last Update Posted: August 20, 2019
Last Verified: August 2019
Keywords provided by Kibow Pharma:
Kibow Biotics
Gut based uremic toxin removal
Additional relevant MeSH terms:
Layout table for MeSH terms
Kidney Diseases
Renal Insufficiency, Chronic
Urologic Diseases
Renal Insufficiency